Navigation Links
Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
Date:8/27/2009

BALTIMORE, Md., Aug. 27 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.

For the fiscal year ended April 30, 2009 the company's operating revenues were $3,710,000 as compared to $1,400,000 for the fiscal year ended April 30, 2008. The Company generated $3,278,000 in revenues in FY 2009 from its Personalized Oncology business, which assists physicians by providing services that may enhance personalized treatment options for their cancer patients, and its Preclinical eValuation business generated $432,000, which assists drug development companies in the preclinical evaluation and development of their drug candidates.

Personalized Oncology expenses for the fiscal 2009 year were $1,623,000 compared to $490,000 in fiscal 2008. The increase was due to the overall growth in the Personalized Oncology business during the year. Preclinical eValuation expenses ended the year at $357,000 compared to zero in fiscal 2008, as fiscal 2009 was the first year that the Company generated revenues and expenses in this business.

Research and Development expenses ended fiscal 2009 at $1,721,000 compared to $200,000 in fiscal 2008. The increase in Research and Development expenses was mainly attributable to the Companies Tumorgraft expansion program that included the acquisition, propagation, storage and characterization of tumors. Additional Research and Development investments were made in Drug Development which includes the salaries, consulting and legal fees incurred in the identification and securing of the Company's future drug
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
2. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
3. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
4. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
7. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
8. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
9. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
10. Malaysian Biotechnology Sector
11. Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has filed its ... and Exchange Commission. The filed Form 20-F includes audited ... 2015. The Form 20-F can be accessed by visiting ...
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... The 2015 ... in-depth study on the current state of the global Propanol market with a focus ... CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... (Nasdaq: NPSP ) announced today that it ... decision whether to,proceed with ex-U.S. development and commercialization ... expects to receive,notification from Nycomed at the end ... NPS on the development of GATTEX(TM) (teduglutide),outside North ...
... presented at AACR-NCI-EORTC International Conference on ... and Cancer Therapeutics in San Francisco, ... Zentaris Inc.,(TSX: AEZ; Nasdaq: AEZS), a global ... today presented an abstract outlining novel,data generated ...
... antibody uses novel approach to "de-cloak" cancers -, ... Inc., (TSX:,ARI), a biotechnology company discovering and developing ... new findings have been,presented from its Trop-2 and ... Trop-2 and CD59 abstracts at the AACR press,conference ...
Cached Biology Technology:NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 3AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 4Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 2Arius announces new findings in Trop-2 and CD59 CANCER antibody programs 3
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
(Date:7/20/2015)... 2015  Acuity Market Intelligence,s latest research "The ... Commerce and Privacy" forecasts that between 2014 and ... be downloaded to smart mobile devices by 2.2 ... is projected to generate more than $67.9 billion ... forecast period.    "Biometrics is at ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... 19, 2009Researchers at The Scripps Research Institute, the University ... used a very sensitive fluorescence technique to find that ... three-dimensional structure (shape), can actually twist itself into a ... folded form is active and the other is inactive, ...
... still be hunters and gatherers, and modern civilization would ... who do not relish the thought of spending our ... cultivated many species of animals and plants found in ... various species provide a fascinating glimpse into the past. ...
... EAST LANSING, Mich. Michigan State University has ... serve as the data coordinating center for the largest ... Informatics Core, established in 2001 and now part of ... and create a repository for data from nearly 3,000 ...
Cached Biology News:Researchers observe single protein dimers wavering between two symmetrically opposed structures 2Researchers observe single protein dimers wavering between two symmetrically opposed structures 3Researchers observe single protein dimers wavering between two symmetrically opposed structures 4Domestication of Capsicum annuum chile pepper provides insights into crop origin and evolution 2MSU lands $2.1 million grant to take part in national autism study 2
... (human), clone 41D GenBank Accession ... Native clusterin purified from human serum ... NaCl and 0.05% sodium azide Quality ... from HeLa cells or MCF-7 cell ...
Component in MasterPure™ Purification Kits...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Biology Products: